Kazia Therapeutics launches new kaziatx.com site

Kazia Therapeutics Limited (KZIA) reports that on August 28, 2026 it launched a new corporate website at www.kaziatx.com.

Rhea-AI Filing Summary

Kazia Therapeutics Limited (KZIA) reports that on August 28, 2026 it launched a new corporate website at www.kaziatx.com. Any prior references to its former website, including www.kaziatherapeutics.com, are now intended to refer to the new URL where applicable.

The site is described as providing enhanced access to information about Kazia’s business, products, services, clinical trials, and corporate developments, and stakeholders are encouraged to review information posted there alongside press releases and SEC disclosures. The information in this report is incorporated by reference into Kazia’s existing Form F-3 registration statements.

Key Figures

Commission File Number: 000-29962 Form F-3 File No.: 333-276091 Form F-3 File No.: 333-281937 +3 more

6 metrics

Commission File Number 000-29962 Exchange Act registration file for Kazia Therapeutics Limited

Form F-3 File No. 333-276091 One of the Form F-3 registration statements incorporating this report by reference

Form F-3 File No. 333-281937 One of the Form F-3 registration statements incorporating this report by reference

Form F-3 File No. 333-294392 One of the Form F-3 registration statements incorporating this report by reference

Website launch date August 28, 2026 Date Kazia launched its new corporate website at www.kaziatx.com

Report signature date August 31, 2026 Date the Form 6-K was signed by the Chief Executive Officer

Key Terms

foreign private issuer, Form 6-K, Form F-3, incorporates by reference, +1 more

5 terms

foreign private issuer regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Form F-3 regulatory

"registration statements on Form F-3 (File Nos. 333-276091"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

incorporates by reference regulatory

"The Company hereby incorporates by reference the information contained herein"

Exchange Act regulatory

"pursuant to the Securities Exchange Act of 1934"

A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kazia Therapeutics Limited (KZIA) announce in this Form 6-K?

Kazia Therapeutics Limited announced that on August 28, 2026 it launched a new corporate website at www.kaziatx.com. The company highlights that the new site offers enhanced access to information on its business, products, services, clinical trials, and corporate developments.

What is the new official website URL for Kazia Therapeutics Limited (KZIA)?

The new official website for Kazia Therapeutics Limited is www.kaziatx.com. Any prior references to the company’s website, including www.kaziatherapeutics.com, in its SEC filings should now be read to refer to this updated URL, as applicable.

How should investors interpret old Kazia (KZIA) filings that reference www.kaziatherapeutics.com?

Kazia states that any prior references in its SEC filings to its website, including www.kaziatherapeutics.com, should now be understood as referring to the new URL www.kaziatx.com, as applicable. This aligns historical disclosures with the updated website address.

Which Kazia (KZIA) registration statements incorporate this 6-K by reference?

Kazia incorporates this report by reference into its Form F-3 registration statements with File Nos. 333-276091, 333-281937, and 333-294392. This means the website-related disclosure becomes part of those shelf registration statements.

Who signed this Kazia Therapeutics Limited (KZIA) Form 6-K and when?

The report was signed on August 31, 2026 by John Friend, who is identified as the company’s Chief Executive Officer. His signature appears on behalf of Kazia Therapeutics Limited as the registrant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 07:31 AM EDT Accepted by SEC EDGAR 08/31/2026 - 07:30 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 000-29962

Kazia Therapeutics Limited.

(Exact Name of Registrant as Specified in Its Charter)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 28, 2026, Kazia Therapeutics Limited (the “Company”) launched a new website. The new website can be found at www.kaziatx.com.

Any prior references to the Company’s website, including references to www.kaziatherapeutics.com, in the Company’s filings with the Securities Exchange Commission (the “SEC”) should be read to refer to the new URL, www.kaziatx.com, as applicable.

The new website has been designed to provide investors, customers, and other stakeholders with enhanced access to information regarding the Company’s business, products, services, clinical trials, and corporate developments. We encourage investors, patients, business partners, researchers, and other stakeholders to review the information we post on our website, in addition to following our press releases and SEC filings.

Incorporation by Reference

The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kazia Therapeutics Limited.
Date: August 31, 2026	By:	/s/ John Friend
	Name:	John Friend
	Title:	Chief Executive Officer

2